The core of the traditional drug business model is the long-term payments made by patients to "control the disease." Gene and cell therapies (such as CAR-T, gene editing) have created a new paradigm of "one treatment, potential cure." For example, the medical economics of a gene therapy for rare diseases priced at millions of dollars can be huge if it can eliminate decades of high care costs for patients at the root cause and restore their productivity. The maturity of gene editing technologies such as CRISPR has expanded this possibility from rare diseases to broad fields such as cancer, cardiovascular diseases, and genetic diseases. Capital significance: This completely changes the value evaluation model of drugs. Although the cost of developing a single therapy is extremely high and the risks are huge, the pricing power, market exclusivity and long-term savings created for payers (medical insurance, commercial insurance) brought by its success can support excess capital returns. Investing in this is a bet on the replacement of the existing huge treatment market by "disruptive treatment solutions", and the imagination of its potential peak sales revenue is exponential.

The era of "one-size-fits-all" broad-spectrum treatment is coming to an end, replaced by "precision medicine" based on genotyping and biomarkers. This is not to shrink the market, but to accurately cut the mass market into countless high-value, high-barrier segments. Tumor immunity: Targeted drugs and cell therapies that target specific mutations, such as PD-1/PD-L1, have created a market worth tens of billions of dollars. Blue Ocean of Rare Diseases: There are more than 7000 rare diseases around the world, most of which are untreatable. Gene therapy has brought hope to these "niche" patient groups, and the market exclusivity and pricing advantages brought by orphan drug designation have made it a golden track with extremely high profit margins. Chronic diseases and aging: Breakthrough therapies for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, as well as diabetes and obesity (such as GLP-1 drugs), face a global patient pool of hundreds of millions. The market capacity reaches hundreds of billions. Significance of capital: Capital needs to have the dual capabilities of "microscope" and "telescope": it can not only deeply identify companies with world-leading platform technology (high barriers, high premiums) on a specific biological pathway or disease mechanism, but also be able to proactively judge which segment tracks are about to explode into the next mass market due to technological maturity.

The value chain of biomedicine is expanding from pure drug research and development and sales to upstream tools and downstream services, forming a huge "life technology ecosystem." Upstream "water sellers": gene sequencing (such as Illumina), gene synthesis, CRIPSIR reagents, laboratory automation equipment, bioinformatics analysis tools (AI Pharmaceuticals), etc., are the innovation infrastructure of the entire industry. Regardless of whether downstream drug research and development is successful or not, these tool providers can obtain sustained and stable demand and cash flow. Downstream service network: CDMO (Contract R & D and Production Organization) for cell therapy, plasma collection and virus vector production for gene therapy, and accompanying diagnostic development, etc., constitute key bottlenecks in industrialization. Investing in these service providers with platform-based and large-scale capabilities is a prudent strategy to share the dividends of industry growth and avoid the risks of single drug research and development. Significance of capital: This provides capital with diversified risk-return allocation options. It can not only invest in high-risk and high-return source innovative pharmaceutical companies, but also deploy in service providers in key links of the industrial chain with greater certainty and stable growth to build a balanced investment portfolio.

Infrastructure audit is an audit of corporate infrastructure construction projects. This includes reviewing the investment, construction and management of infrastructure projects such as corporate buildings, roads, bridges, and water conservancy facilities. Our audit team will conduct a detailed review of all aspects of the project's budget, bidding, contract, construction, settlement and other aspects in accordance with relevant regulations and standards to ensure the compliance and authenticity of the project. After completing the audit, we will issue an infrastructure audit report to evaluate the investment efficiency and construction management of the project, and put forward improvement opinions and suggestions.

Beyond financial returns, biomedicine and genetic engineering carry the most fundamental demands of mankind-health and longevity. Successful investment in this field means that capital has participated in the grand cause of extending human healthy life, improving the quality of life, and even rewriting genetic destiny. This deep-seated social value gives companies a strong brand moat, policy support (such as rapid review channels) and talent appeal. Capital significance: This gives the relevant investment the attribute of "permanent options". Even if a certain technology fails to meet business expectations for the time being, its accumulated scientific understanding, technology platform and talent team may produce disruptive results at some point in the future. Therefore, capital needs to uphold a true long-term doctrine, understand the uncertainty of scientific exploration, and be willing to provide long-term support to teams with grand visions and solid scientific logic. This kind of investment is the deepest binding between capital and the narrative of human progress.

To sum up, biomedicine and genetic engineering are no longer a simple "high-risk, high-return" sector, but a compound defined by paradigm subversion, precise subdivision, ecological expansion, efficiency revolution and social values. Strategic opportunities. The role of capital must change from a purely financial investor to a "strategic partner" who understands scientific logic. Successful investment requires both forward-looking judgment on scientific trends, fine management of R & D risks, overall insight into the industrial chain, and deep recognition of social values. In this great journey of conquering disease and decoding life, capital is not only fuel, but also a catalyst and co-worker. What it pursues is not only a multiple of financial returns, but also the irreplaceable ultimate return that can be gained by participating in pushing the boundaries of human biology and investing in a healthier future. This is a sustained and powerful civilizational dividend brought by allocating capital to the deepest human needs.